

Image Analysis Group (IAG) Expands U.S. Presence with New Boston-Area Office Opening

IAG's strategic Cambridge, MA location strengthens proximity to biotech innovators and accelerates support for imaging-driven clinical trials.


CAMBRIDGE, MA, UNITED STATES, August 26, 2026 /EINPresswire.com/ -- [Image Analysis Group \(IAG\)](#), a global leader in clinical trial imaging and AI-driven biomarkers for clinical trials, this summer announced the opening of its new U.S. office in [Cambridge, Massachusetts](#). The new office places IAG at the center of one of the world's most active biotech and pharmaceutical hubs.

IAG's Boston-area office brings its operations and business development teams closer to the companies shaping the future of clinical development. The location provides a strong local base to support sponsors, strengthen partnerships, and respond quickly to emerging clinical trial needs across the region.

The expansion reflects IAG's continued growth and commitment to supporting sponsors and CROs across oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic and metabolic diseases. Being on the ground in Boston enables IAG to engage more directly with biotech and pharma teams advancing innovative Phase I-III trials and imaging-intensive programs, reinforcing its commitment to being accessible, collaborative, and present where critical development decisions are made.



Image Analysis Group (IAG)



IAG's new Cambridge, MA office places the company at the center of one of the world's most active biotech and pharmaceutical hubs.

The new office is expected to drive local job creation, with planned hires across clinical imaging operations, data science, regulatory support, and business development functions over the next 12–24 months.

“This expansion marks an important milestone in IAG’s growth strategy. Boston is a global epicenter for biotech innovation, and establishing a presence here allows us to work more closely with our clients as they advance complex, imaging-driven clinical trials. By being on the ground, we can collaborate more effectively, respond faster, and deliver the high-quality imaging insights that are critical to accelerating drug development,” said Olga Kubassova, Chief Executive Officer of Image Analysis Group (IAG).

“Cambridge and the greater Boston area represent one of the world’s most concentrated and dynamic life-sciences ecosystems. Our new office sits at the heart of what is often described as the densest square mile of biotech research and innovation anywhere, and is surrounded by pioneering biotech companies, pharmaceutical partners, academic institutions and clinical research leaders,”

“Having a dedicated local presence enables us to build deeper, more responsive relationships with the sponsors and CROs advancing next-generation therapies. As someone who has spent his career at the intersection of UK and U.S. life sciences, I see this office as a natural extension of that bridge, giving our team the local footprint to support sponsors’ imaging needs from early trial design and protocol development through to regulatory submission.” said Mike Fisher, PhD, FRSC, Vice President of Business Development & Strategic Partnerships at Image Analysis Group (IAG).

Boston’s globally recognized life sciences ecosystem gives IAG proximity to leading biotech innovators, academic institutions, and clinical research centers. This expansion enhances IAG’s ability to deliver responsive, high-quality imaging services and AI-powered analytics that enable more efficient, data-driven clinical trials.

The new office will support end-to-end imaging services, including trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery, helping sponsors accelerate development timelines and improve decision-making.

Global Reach and Operations

Image Analysis Group supports clinical trials across North America, Europe, and Asia-Pacific, partnering with sponsors and CROs to deliver consistent, high-quality imaging analysis across global, multi-center studies. With established operational hubs and experience navigating diverse regulatory environments, IAG ensures seamless study execution, standardized imaging protocols, and centralized data harmonization, enabling sponsors to run complex international trials with confidence.

About Image Analysis Group

Founded in 2007 and headquartered in London, Image Analysis Group (IAG) is a global specialist Imaging Clinical Research Organization (iCRO). IAG partners with leading pharmaceutical, biotechnology and medtech companies to design, execute and deliver imaging-based clinical trial endpoints across oncology, inflammatory disease, musculoskeletal, cardiometabolic and rare disease indications. Our proprietary [DYNAMIKA™](#) platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting and real-time trial oversight. With teams across the UK, US, EU and India, IAG accelerates drug development timelines and strengthens the scientific integrity of imaging in regulatory submissions.

W: www.ia-grp.com

E: contact@ia-grp.com

Marie Fussell

Image Analysis Group (IAG)

+1 267-857-8638

press@ia-grp.com

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/937225987>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.